ZENI: Q1 2026 saw 10% revenue growth, positive earnings, and major new contracts in core markets
· Issued by Zenicor Medical Systems AB
Revenue grew 10% year-over-year in Q1 2026, with both operating and net profit turning positive. Key contracts in the UK, Sweden, and Finland boosted the order backlog, and net debt was reduced, supporting a stable outlook for continued growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
